Results 141 to 150 of about 37,688 (274)

High‐Altitude Adaptation of Frogs (Case Study: Nanorana parkeri): From Physiological Phenotypes to AltitudeOmics

Integrative Zoology, EarlyView.
High altitudes are challenging for the animals that inhabit these environments. The Xizang plateau frog (Nanorana parkeri) survives in high‐altitude environments through a synergistic strategy of metabolic remodeling and protein expression adjustment to optimize energy efficiency and enhance cellular protection.
Xuejing Zhang, Yonggang Niu, Shengkang Men, Yanghuilin Zhang, Xiaolong Tang, Kenneth B. Storey, Qiang Chen   +6 more
wiley   +1 more source

Characterizing the fecal microbiome in patients on the ketogenic diet for drug resistant epilepsy

Heliyon
Background: The ketogenic diet is a dietary therapy with anti-seizure effects. The efficacy of the diet is variable, with initial animal studies suggesting the intestinal microbiome may have a modulating effect.
Alexander Freibauer, Nikhil Pai, Rajesh RamachandranNair   +2 more
doaj   +1 more source

GPS analysis of a team competing at a national Under 18 field hockey tournament [PDF]

, 2018
The purpose of this study was to utilise global-positioning system (GPS) technology to quantify the running demands of national Under 18 field hockey players competing in a regional field hockey tournament.
Van der Merwe, Frans H
core  

Dual pharmacological targeting of coactivator‐associated arginine methyltransferase 1 (CARM1) and salt inducible kinase (SIK) drives ketogenesis in both hepatocytes and mice

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Ketone bodies are liver‐derived circulating energy metabolites that positively impact most hallmarks of ageing. Ketone bodies increase during calorie restriction and fasting, two of the more widely perceived methods to increase health span.
Tábata Bergonci, Troels Kjær Rosenbæk, Samuel J. Windross, Ulrik B. Keiding, Estéfano Pinilla, Katrine P. Stuckert, Jakob Hansen, Camilla B. Nielsen, Jemila Peter Gomes, Lucy R. Davies, Johan Palmfeldt, Volker Loeschcke, Charlotte U. Andersen, Ulf Simonsen, Thomas B. Poulsen, Mogens Johannsen   +15 more
wiley   +1 more source

Intravenous immunoglobulin and febrile status epilepticus in children with Dravet syndrome: A retrospective multicentre study

Developmental Medicine &Child Neurology, EarlyView.
This multicenter retrospective study evaluated the use of intravenous immunoglobulin (IVIG) in 14 children with Dravet syndrome as a preventive strategy against febrile status epilepticus. Over a 6‐month period, IVIG was associated with a significant reduction in hospitalizations for febrile status epilepticus.
Romane Marc, Nicole Chemaly, Mathieu Kuchenbuch, Caroline Espil‐Taris, Elodie Lametery, Hélène Maurey, Sylviane Peudenier, Sylvie Nguyen The Tich, Rima Nabbout, Claire Bar   +9 more
wiley   +1 more source

Clinical and genetic characterization of intellectual disability

Developmental Medicine &Child Neurology, EarlyView.
This study examines the etiological factors and comorbidities in a large cohort of Finnish patients with intellectual disability. Genetic causes—including chromosomal abnormalities and pathogenic gene variants—were more frequently identified in individuals with moderate to profound intellectual disability.
Aarni Venetvaara, Minna Kraatari‐Tiri, Jussi‐Pekka Tolonen, Marko Merikukka, IDGEN Study Group, Hannaleena Kokkonen, Teija Paakkola, Susanna Varis, Antti Dahl, Jarmo Körkkö, Jonna Komulainen‐Ebrahim, Jukka Moilanen, Johanna Uusimaa, Outi Kuismin, Elisa Rahikkala   +14 more
wiley   +1 more source

Caring for Australians and New ZealandeRs with kidney Impairment guideline commentary on kidney disease: improving global outcomes 2025 guidelines for diagnosis and management of autosomal polycystic kidney disease

Internal Medicine Journal, EarlyView.
Abstract Autosomal polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease. The international guideline developer, Kidney Disease: Improving Global Outcomes (KDIGO), published a 2025 clinical practice guideline reflecting advances in genetic testing and the first disease‐modifying agent, tolvaptan.
Mia E. Abdy, Kitty St Pierre, Emily Major, Stephen I. Alexander, Brydee Cashmore, Helen Coolican, Vanessa Cullen, Jessica Dawson, Kelly Lambert, Vincent W. Lee, Amali Mallawaarachi, Gopala Rangan, Judy Savige, Santosh Varughese, David J. Tunnicliffe, Andrew J. Mallett, on behalf of the CARI Guidelines Steering Committee, Emily See, Leanne Brown, Jonathan Craig, Jeffrey Ha, Rathika Krishnasamy, Casey Light, Emmy O'Neill, Thu Nguyen, Hannah Smith, Andrea Viecelli   +26 more
wiley   +1 more source

Failure of Urine Dipsticks to Detect Ketosis in Rats [PDF]

, 2011
Bidlingmaier, Martin, Bielohuby, Maximilian, Menhofer, Dominik, Stoehr, Barbara J. M.   +3 more
core   +1 more source

Epileptic–Dyskinetic Encephalopathy Associated with a PPP3CA Variant: Expansion of the Phenotypic Spectrum

Movement Disorders Clinical Practice, EarlyView.
Bruno Antunes Contrucci, Ursula Thomé, Larissa Aparecida Batista, Ana Laura Volpi Martins Lorenzoni, Carla Andrea Cardoso Tanuri Caldas, Americo Ceiki Sakamoto, Israel Gomy, Lisandra Mesquita Batista, Marcela Lopes de Almeida, Ana Paula Andrade Hamad, Guillermo Andrey Ariza Traslaviña   +10 more
wiley   +1 more source

Ketogenic diet therapy for epilepsy in Australia: insights from the Pharmaceutical Benefits Scheme

Internal Medicine Journal, EarlyView.
Abstract Ketogenic diet therapy is an effective non‐pharmacological treatment for drug‐resistant epilepsy. Since the first item was listed on the Pharmaceutical Benefits Scheme (PBS) in 2009, we report a 21.6‐fold increase in annual PBS expenditure on items related to ketogenic diet therapy.
Neha Kaul, Lillian King, Susanna Chen, Patrick Kwan, Terence J. O'Brien   +4 more
wiley   +1 more source